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Abstract
Background: Transportin-SR2 (TRN-SR2, TNPO3, transportin 3) was previously identified as an interaction partner of
human immunodeficiency virus type 1 (HIV-1) integrase and functions as a nuclear import factor of HIV-1. A
possible role of capsid in transportin-SR2-mediated nuclear import was recently suggested by the findings that a
chimeric HIV virus, carrying the murine leukemia virus (MLV) capsid and matrix proteins, displayed a transportin-SR2
independent phenotype, and that the HIV-1 N74D capsid mutant proved insensitive to transportin-SR2 knockdown.
Results: Our present analysis of viral specificity reveals that TRN-SR2 is not used to the same extent by all
lentiviruses. The DNA flap does not determine the TRN-SR2 requirement of HIV-1. We corroborate the TRN-SR2
independent phenotype of the chimeric HIV virus carrying the MLV capsid and matrix proteins. We reanalyzed the
HIV-1 N74D capsid mutant in cells transiently or stably depleted of transportin-SR2 and confirm that the N74D
capsid mutant is independent of TRN-SR2 when pseudotyped with the vesicular stomatitis virus glycoprotein
(VSV-G). Remarkably, although somewhat less dependent on TRN-SR2 than wild type virus, the N74D capsid mutant
carrying the wild type HIV-1 envelope required TRN-SR2 for efficient replication. By pseudotyping with envelopes
that mediate pH-independent viral uptake including HIV-1, measles virus and amphotropic MLV envelopes, we
demonstrate that HIV-1 N74D capsid mutant viruses retain partial dependency on TRN-SR2. However, this
dependency on TRN-SR2 is lost when the HIV N74D capsid mutant is pseudotyped with envelopes mediating
pH-dependent endocytosis, such as the VSV-G and Ebola virus envelopes.
Conclusion: Here we discover a link between the viral entry of HIV and its interaction with TRN-SR2. Our data
confirm the importance of TRN-SR2 in HIV-1 replication and argue for careful interpretation of experiments
performed with VSV-G pseudotyped viruses in studies on early steps of HIV replication including the role of capsid
therein.
Background
Retroviruses stably integrate the DNA copy of their
RNA genome into the host cell chromatin. However,
there are marked differences between the distinct
families of retroviruses regarding their capacity to repli-
cate in non-dividing cells. The lentivirinae such as the
human immunodeficiency virus type 1 (HIV-1) can
infect dividing and non-dividing cells such as macro-
phages, dendritic cells or CD4+ memory T-cells [1].
Rous sarcoma virus (RSV) can also infect non-dividing
cells such as neurons or growth-arrested cells, but with
less efficiency than HIV [2]. In contrast, the g-retrovirus
M o l o n e ym u r i n el e u k e m i av i r u s( M L V )i n f e c t so n l y
dividing cells efficiently [3]. To date, this difference can-
not be explained. The prevailing hypothesis has been
that lentiviruses adopt a specific mechanism for active
nuclear import through the nucleopore, and that other
retroviruses must depend on the breakdown of the
nuclear membrane during mitosis for chromatin access
in order to achieve integration [3-5]. More recently, a
role for retroviral capsid was proposed in replication
d e t e r m i n a t i o ni nn o n - d i v i d ing cells [6,7]. After HIV
entry in the target cell, the viral core is released into the
cytoplasm. On its way to the nucleus, viral capsid (CA)
is shed from this nucleoprotein complex, containing
both viral and cellular proteins, in an ill-defined process
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while the viral enzyme reverse transcriptase (RT) tran-
scribes the RNA genome into a cDNA copy.
After reverse transcription, the preintegration complex
(PIC) is transported through the nuclear pore complex
(NPC). The NPC is a specialized channel ~40 nm in
diameter [9] that supports passive diffusion of small
molecules and ions and facilitates receptor-mediated
translocation of proteins and ribonucleoprotein com-
plexes above 40 kDa. Since the HIV-1 PIC is a nucleo-
protein complex with an estimated diameter of 56 nm
[10], it requires conformational changes and active
transport through the NPC. Many attempts have been
made to determine the viral and cellular factors mediat-
ing nuclear import of the HIV PIC (for a review see
[11]). Viral protein R (Vpr), matrix protein (MA), inte-
grase (IN) and the DNA flap have each been proposed
as the main viral determinant for nuclear trafficking of
the PIC, but these findings were not readily reproduced
in subsequent studies. As cellular cofactors, importin-a/
importin-b [12-15] and importin-7 [16-19] have been
investigated as PIC transporters, but their role in HIV
replication has not been thoroughly validated or con-
firmed. Also, importin-a3 has very recently been impli-
cated in HIV nuclear import [20].
Recently, we identified the cellular protein transportin-
SR2 (TRN-SR2, TNPO3, transportin 3), encoded by the
TNPO3 gene, as the nuclear import factor of HIV [21].
Two genome-wide RNAi screens [22,23], but not others
[24,25] also identified TRN-SR2 as a cofactor of HIV
replication. Transportin-SR2 (TRN-SR2) was first identi-
fied as an important nuclear import factor for phos-
phorylated splicing factors of a family of serine/arginine-
rich proteins (SR proteins) [26-28]. It has also been
shown that TRN-SR2 imports other proteins not
belonging to the SR protein family [29]. We identified
TRN-SR2 as a binding partner of HIV-1 integrase in a
yeast two-hybrid screen [21], and reverse yeast two-
hybrid screening demonstrated that none of the other
HIV proteins directly interacts with TRN-SR2. In cells
transiently or stably depleted of TRN-SR2, HIV replica-
tion was severely hampered due to a defect in the
nuclear import of the HIV PIC [21]. Using GFP-labeled
HIV, a direct effect of TRN-SR2 on the nuclear import
of PICs was also visualized. Finally, TRN-SR2 was
required for HIV infection of both dividing and non-
dividing cells, implying that a similar nuclear import
pathway is used in different stages of the cell cycle.
A recent study confirmed the effect of TRN-SR2
knockdown on HIV-1 vector transduction [30]. In that
study the specificity for different retroviral vectors and
the direct interaction of TRN-SR2 with the integrase
proteins from different retroviruses were examined, and
the authors corroborated the direct interaction between
recombinant TRN-SR2 and HIV-1 IN. Although TRN-
SR2 was found to be a rather prolific IN binder, display-
ing affinity for multiple retroviral integrases, no clear
correlation between the interactions of various inte-
grases with TRN-SR2 and dependence on TRN-SR2
during viral vector transductions was observed. In addi-
tion, a chimeric reporter virus composed of both HIV
and MLV proteins (MHIV) carrying the MLV MA, p12
and CA proteins instead of the HIV-1 MA and CA pro-
teins [6,31], which was also pseudotyped with the vesi-
cular stomatitis virus glycoprotein (VSV-G) envelope,
appeared to be insensitive to TRN-SR2 knockdown.
Although no evidence was provided that TRN-SR2 and
CA physically interact, it was proposed that the TRN-
SR2 dependency of HIV-1 infection is mediated by CA
and not by HIV-1 integrase [30]. In a follow up study,
t h er o l eo fC Ai nt h eT R N - S R 2r e q u i r e m e n to fH I V - 1
replication was examined in more detail [32]. Ectopic
expression of a C-terminally truncated version of the
cleavage and polyadenylation specific factor 6 (CPSF6)
resulted in a block of HIV replication. An HIV-1 strain
with a mutation in CA (N74D) was capable of escaping
this phenotype. Interestingly, the VSV-G pseudotyped
HIV-1 N74D CA mutant virus appeared to be indepen-
dent of TRN-SR2 for infection of both dividing and
non-dividing cells [32]. Here we enter the debate by re-
examining whether HIV CA is involved in the TRN-SR2
requirement of HIV. We compared wild type and VSV-
G pseudotyped viral vectors and studied the N74D CA
mutant which was reported to be independent of TRN-
SR2. To our surprise, the phenotype of the N74D CA
mutant virus appeared to be dependent on the viral
entry route. Whereas the mutant virus was insensitive
to TRN-SR2 depletion when pseudotyped with VSV-G,
the same mutant proved to be still dependent on TRN-
SR2, although to a somewhat lesser extent, when retain-
ing the HIV envelope. Our results are suggestive of a
role for capsid mutations having an indirect effect on
the interaction between HIV and TRN-SR2, probably by
affecting the processes of uncoating or docking to the
nuclear pore that precede the previously demonstrated
interaction between IN and TRN-SR2.
Results
Lentiviral specificity of TRN-SR2
We previously identified TRN-SR2 as an important cel-
lular cofactor mediating HIV-1 nuclear import [21].
HIV-2 was also dependent on TRN-SR2, although MLV
did not appear to be dependent. Here we verified
whether TRN-SR2 acts as a lentivirus-specific nuclear
import factor. We transduced HeLaP4 cell lines transi-
ently depleted of TRN-SR2 with different retroviral vec-
tors (Figure 1), and a mismatch siRNA was run in
parallel to exclude off-target effects while mock
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procedure. TRN-SR2 knockdown was verified by western
blot (Figure 1A). Three days after siRNA transfection cells
were transduced with concentrated VSV-G pseudotyped
viral vectors derived from HIV-1, SIV (simian immunode-
ficiency virus), EIAV (equine infectious anemia virus), FIV
(feline immunodeficiency virus) or MLV. Vector prepara-
tions were adjusted to yield 30-60% GFP positivity in
mock transfected cells. Three days after transduction cells
were fixed and analyzed for the overall GFP fluorescence
by flow cytometry (Figure 1B). After TRN-SR2 knock-
down, transduction by either HIV-1 or SIV vectors was
inhibited up to 90% and 95%, respectively. The EIAV vec-
tor was also sensitive to TRN-SR2 depletion, although to a
lesser extent (50% inhibition of transduction efficiency).
Transductions by the FIV and MLV vectors were modestly
affected (12% and 29% inhibition, respectively) when
compared to mismatch siRNA-transfected cells. From this
analysis, we conclude that TRN-SR2 is a cellular cofactor
important for transduction by some, but not all VSV-G
pseudotyped lentiviral vectors.
The central DNA flap is a structure in the reverse
transcribed DNA genome of lentiviruses that is absent
from retroviruses like MLV [33,34]. Since the DNA flap
has been implicated in HIV nuclear import [35-40], we
examined whether the central DNA flap might be
important for the TRN-SR2 requirement of HIV-1.
HeLaP4 cell lines transiently depleted of TRN-SR2 and
control cells were challenged with 3 dilutions of HIV-1-
derived VSV-G pseudotyped lentivectors carrying a
cPPT/CTS sequence in sense (WT) or antisense orienta-
tion (Flap-). In antisense orientation, the cPPT/CTS
sequence does not yield a functional flap. Vectors lack-
ing a functional flap are known to display a 3- to 6-fold
reduction in transduction efficiency [37]. Three days
after transduction, overall GFP fluorescence was mea-
sured by flow cytometry (Additional file 1: Figures S1A
and S1B). The vector dilutions yielded 90%, 60% or 20%
GFP positive control cells, respectively. Transduction by
the lentiviral vectors with (Additional file 1: Figure S1A)
or without DNA flap (Additional file 1: Figure S1B) was
inhibited up to 70% in TRN-SR2 depleted cells and at
all dilutions used. Next, we tested the effect of DNA
flap mutations on the multiple-round infectivity of HIV-
1 virus strain NL4-3 in TRN-SR2 depleted HeLaP4 cells
(Additional file 1: Figures S1C and S1D). We infected
HeLaP4 cells transiently depleted of TRN-SR2 and con-
trol cells with 3 dilutions of infectious HIV-1NL4-3LAI
cPPT wild type virus (WT) (Additional file 1: Figure
S1C) and HIV-1NL4-3LAI cPPTD (Flap-) virus (Addi-
tional file 1: Figure S1D). The latter contains a mutated
cPPT sequence which prevents formation of the DNA
flap during reverse transcription and shows a 10- to
100-fold replication defect depending on the viral infec-
tion dose [35,38]. The HeLaP4 cells contain a b-galacto-
sidase (b-gal) reporter gene under control of the HIV-1
LTR promoter. Three days after infection b-galactosi-
dase activity was measured. The data demonstrate
reduced infectivity of the flap-negative virus, which
becomes more apparent at lower MOIs as was pre-
viously reported [35,38]. TRN-SR2 knockdown inhibited
replication of wild type and flap-negative virus to the
same extent (up to 80% inhibition) demonstrating that
the DNA flap is not required for the TRN-SR2 depen-
dency of HIV-1 replication.
The MLV capsid confers TRN-SR2 independence to
chimeric HIV-1
Next we investigated which viral proteins, present in the
PIC, are responsible for the TRN-SR2 independent phe-
notype displayed by the MLV vector. We used the HIV-
MLV chimeric viruses (MHIV) previously constructed
by the Emerman group [6,31]. In MHIV-mMA12CA the
HIV MA and CA proteins are replaced by the MLV
MA, CA and p12 proteins. In MHIV-mIN, the HIV IN
protein is replaced by the MLV IN. MHIV-mMA12CA
cannot infect non-dividing cells, but MHIV-mIN infects
non-dividing cells as well as dividing cells [6,31]. Since
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Figure 1 Effect of TRN-SR2 knockdown on transduction
efficiency of various retroviral vectors. (A) TRN-SR2 knockdown
in HeLaP4 cells 3 days post siRNA transfection visualized by western
blotting. b-tubulin was detected as a control for equal loading. (B)
HeLaP4 cells were transfected with siRNAs for knockdown of TRN-
SR2 (siTRN-SR_2), with a mismatched control siRNA (siTRN-SR_2MM)
or were mock transfected (mock). Three days post transfection cells
were transduced with different VSV-G pseudotyped retroviral vectors
encoding GFP. The overall GFP fluorescence was measured by flow
cytometry and is expressed as the percentage relative to the control
cell values. Results represent mean values ± standard deviation (SD)
of at least 3 independent experiments each performed in triplicate.
In each experiment newly produced viral vectors were used.
Thys et al. Retrovirology 2011, 8:7
http://www.retrovirology.com/content/8/1/7
Page 3 of 17these viruses are poorly infectious, VSV-G pseudotyping
of the chimeric viruses during productions is absolutely
required to obtain infectious virions. Construction of
MLV-based chimeric proviruses did not generate infec-
tious virions [6].
We evaluated the effect of siRNA-mediated TRN-SR2
knockdown in HeLaP4 cells on infection by both MHIV
chimeric viruses (Figure 2A). We used VSV-G pseudo-
typed single-round MHIV-mMA12CA and MHIV-mIN
viruses and their parental HIV-1 and MLV vector, all
expressing the firefly luciferase reporter gene (Fluc).
HeLaP4 cells transiently depleted of TRN-SR2 and control
cells were infected with concentrated VSV-G pseudotyped
viral stocks. Luciferase activities were measured 3 days
post infection and were normalized to the levels in mock
transfected control cells (Figure 2A). As previously
reported [21-23,30], the MLV vector displayed only mod-
est sensitivity to TRN-SR2 knockdown (33% inhibition of
infectivity in TRN-SR2 knockdown cells compared to mis-
match siRNA transfected cells). Surprisingly, the MHIV-
mMA12CA chimeric virus was only partially sensitive to
TRN-SR2 knockdown (34% inhibition in TRN-SR2 knock-
down cells compared to mismatch siRNA transfected
cells). In contrast, both the MHIV-mIN virus and the par-
ental HIV-1 reporter virus were severely impaired by
TRN-SR2 knockdown (77% and 87% inhibition, respec-
tively). These results are comparable to those described by
Krishnan and colleagues [30]. Swapping of HIV MA and
CA proteins with those of MLV apparently interferes with
the requirement for TRN-SR2 during infection but repla-
cing the IN of HIV-1 by that of MLV does not alter the
TRN-SR2 dependency of the chimeric virus.
Two alternative explanations for these results are possi-
ble. The viral CA may determine the interaction between
TRN-SR2 and the HIV-1 PIC as was proposed by Krish-
nan et al. [30]; and by replacing the HIV-1 CA and MA
proteins by their non-interacting MLV counterparts, this
interaction could be inhibited, rendering infection of the
MHIV-mMA12CA virus partially independent of TRN-
SR2. Substituting the integrases in this case would have no
effect. Alternatively, TRN-SR2 can interact with both
HIV-1 and MLV IN and, as a result, the MHIV-mIN virus
would remain dependent on TRN-SR2. However, recom-
binant His-tagged HIV-1 IN could pull down endogenous
TRN-SR2 in cellular lysates, but recombinant His-tagged
MLV IN could not [21]. Still, this interaction could have
gone undetected due to low concentrations of endogenous
TRN-SR2 in the cell lysate which are difficult to detect by
western blot alone. Therefore, we reinvestigated the direct
protein-protein interaction using AlphaScreen technology
and recombinant GST-TRN-SR2 and IN-His6 (Figure 2B).
As negative controls for binding to GST-TRN-SR2, we
used two different His6-tagged proteins; His6-GaoA,t h e
His6-tagged human heterotrimeric G protein a oA subunit
[41], and His6-Roc-COR, a His6-tagged GTPase Ras of
complex proteins (Roc) domain in tandem with its C-
terminal domain of Roc (COR) of the leucine rich repeat
kinase 2 protein (LRRK2) from Chlorobium tepidum [42].
The different His6-tagged proteins were titrated against a
fixed concentration of GST-TRN-SR2 (10 nM). As
expected, no interaction between His6-GaoA or His6-Roc-
COR and GST-TRN-SR2 was detected under our assay
conditions (Figure 2B). In this assay, we did observe bind-
ing of GST-TRN-SR2 to both His6-tagged HIV-1 IN and
MLV IN with an apparent Kd of 36.3 ± 2.3 nM for HIV-1
IN and an even lower Kd of 17.5 ± 0.5 nM for MLV IN, an
0
20
40
60
80
100
120
140
HIV-1 MLV MHIV-mMA12CA MHIV-mIN
F
l
u
c
 
L
U
/
µ
g
 
p
r
o
t
e
i
n
mock
siTRN-SR_2
siTRN-SR_2MM
A
B
K :  36.3  ±  2.3  nM d
2 R:   0.9945
K :  17.5  ±  0.5  nM d
2 R   :  0.9933
-  33  % -  34  %
0 50 100 150
0
20000
40000
60000
80000
[protein]   (nM) 0
A
l
p
h
a
S
c
r
e
e
n
 
c
o
u
n
t
s
HIV-1  IN
Roc-COR
GαoA
60000
40000
20000
0
02 0 4 0 6 0 80
[IN]   (nM) 0
MLV  IN
Figure 2 HIV containing MLV capsid is largely TRN-SR2
independent, HIV with MLV integrase is not. (A) HeLaP4 cells
depleted of TRN-SR2 (siTRN-SR_2) and control cells (mock and
siTRN-SR_2MM) were infected with VSV-G pseudotyped HIV-1 single-
round virus, MLV vector, or with the chimeric viruses MHIV-
mMA12CA or MHIV-mIN. In MHIV-mMA12CA the HIV MA and CA
proteins are replaced by the MLV MA, CA and p12 proteins. In
MHIV-mIN the HIV IN protein is replaced by MLV IN. Three days post
infection cells were lysed and Fluc activity was measured and
normalized to the total amount of protein in the cell lysates. Results
are shown as the mean values of relative light units per μg protein
(Fluc RLU/μg protein) ± SD compared to mock transfected cells and
represent 2 independent experiments each performed in triplicate.
The arrows indicate the relative inhibition of infectivity in TRN-SR2
depleted cells compared to mismatch siRNA tranfected cells. (B)
Direct interactions between recombinant GST-TRN-SR2 and His6-
tagged HIV-1 IN or MLV IN were measured by AlphaScreen. As
negative controls for binding to GST-TRN-SR2 both His6-GaoA and
His6-Roc-COR were used. 10 nM of GST-TRN-SR2 was incubated with
different concentrations of His6-tagged proteins and complexes
were bound to glutathione donor beads and nickel-chelate
acceptor beads. Light emission was measured using an EnVision
Multilabel Reader. The apparent equilibrium dissociation constants
(Kd) were calculated with GraphPad Prism 5 and are indicated on
the graphs.
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are consistent with the hypothesis that TRN-SR2 binds to
both HIV-1 and MLV IN in the context of a viral PIC,
explaining the TRN-SR2 dependency of MHIV-mIN, the
chimeric HIV virus containing MLV IN. However, this
does not explain the TRN-SR2 independent phenotype of
the MLV vector and the MHIV-mMA12CA virus. More-
over, a CA mutant virus (HIV-1 N74D) has recently been
described to be insensitive to TRN-SR2 knockdown [32].
These findings prompted us to investigate in more detail a
possible role of HIV-1 CA in the TRN-SR2 requirement of
HIV-1 replication.
The HIV-1 N74D CA mutant virus still requires TRN-SR2
for efficient infection
A VSV-G pseudotyped HIV-1 N74D CA mutant virus
was recently reported to be insensitive to TRN-SR2
knockdown [32]. Krishnan et al. [30] hypothesized that
the TRN-SR2 dependency of HIV-1 is dictated by HIV-
1 CA instead of IN. To test this hypothesis, we infected
HeLaP4 cells transiently depleted of TRN-SR2 with
VSV-G pseudotyped wild type and N74D CA mutant
luciferase reporter viruses (Figures 3A and 3B) or with
replication competent HIV-1 NL4-3 wild type and
N74D mutant virus (Figures 3C and 3D). The infectivity
of the VSV-G pseudotyped wild type and N74D CA
mutant luciferase reporter viruses was measured by Fluc
activity. Interestingly, after normalization of the virus
stocks based on p24 measurements (PerkinElmer, HIV-1
p24 ELISA kit), the VSV-G pseudotyped N74D CA
mutant virus appeared 5-fold more infectious (compare
Figures 3A and 3B). In repeated infection experiments,
the VSV-G pseudotyped N74D mutant virus consistently
displayed 5- to 10-fold higher luciferase counts than
pseudotyped wild type virus (data not shown). We con-
firmed the TRN-SR2 independent phenotype of the
VSV-G pseudotyped N74D CA mutant (Figure 3B) in
comparison to the pseudotyped wild type virus (75%
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knockdown cells compared to the mismatch siRNA
transfected cells) (Figure 3A). Similar results were
obtained with a b-galactosidase readout (data not
shown).
Subsequently, we infected HeLaP4 cells transiently
depleted of TRN-SR2 with replication competent wild
type and N74D mutant viruses. Both viruses carried the
HIV-1 envelope proteins gp120 and gp41. To allow mul-
tiple round replication, three days after infection b-
galactosidase activity was measured as readout for viral
infectivity. Virus stocks were normalized for p24 content
(PerkinElmer p24 ELISA kit). The N74D mutant again
yielded higher b-galactosidase counts (compare Figures
3C and 3D), although the difference in infectivity was
less pronounced (1.5-fold higher infectivity than wild
type virus) than with the VSV-G pseudotyped N74D CA
mutant (5- to 10-fold higher infectivity than wild type
virus, compare Figures 3A and 3B). In repeated experi-
ments using viruses carrying the HIV-1 envelope, we
consistently observed a 1.5- to 3-fold higher infectivity
of the N74D CA mutant measured via b-galactosidase
activity (data not shown). We observed that both HIV-1
NL4-3 WT virus (Figure 3C) and the N74D CA mutant
(Figure 3D) required TRN-SR2 for efficient infection of
HeLaP4 cells (average reduction of infectivity of 80%
and 50% in TRN-SR2 knockdown cells, respectively),
although the N74D CA mutant virus was less sensitive
to TRN-SR2 depletion. Nevertheless, a prominent altera-
tion in the TRN-SR2 dependency of the N74D CA
mutant was observed when using the VSV-G envelope
(complete insensitivity to TRN-SR2 knockdown, Figure
3B) or the HIV-1 envelope (intermediate sensitivity to
T R N - S R 2k n o c k d o w n ,F i g u r e3 D ) .A st h e s ef i n d i n g s
suggest, the difference in TRN-SR2 dependency dis-
played by the N74D CA mutant in the multiple round
compared with the single round infections was depen-
dent on the envelope proteins; we investigated pro-
longed multiple round replication of the HIV-1 N74D
CA mutant carrying a wild type envelope using HeLaP4
cells stably depleted of TRN-SR2 knockdown.
We generated stable TRN-SR2 knockdown cell lines
by transducing HeLaP4 cells with one of two different
lentiviral vectors expressing shRNA targeting the TRN-
S R 2m R N A( s h T R 3a n ds h T R 4 )a n dac o n t r o lc e l ll i n e
using a control vector expressing a scrambled shRNA
(shSCR). TRN-SR2 knockdown was verified with Wes-
tern blotting (Figure 4A) and QPCR (Figure 4B). When
visualized by Western blotting, TRN-SR2 knockdown in
the shTR3 or shTR4 HeLaP4 cells was comparable to
the level of knockdown obtained by transient transfec-
tion of siTRN-SR_2 (compare Figures 4A and 1A).
When measured by QPCR, expression of shTR3 or
shTR4 decreased the amount of TRN-SR2 mRNA copies
for 80% or 70% respectively in comparison with control
cells (Figure 4B). Using immunostaining and FACS ana-
lysis of the CD4 surface receptor expressed by the TRN-
SR2 depleted cells and control cells, comparable CD4
expression levels in the knockdown cells and control
cells were observed (Figure 4C). As expected, no CD4
expression was observed in 293T cells which were used
as a negative control to exclu d en o n - s p e c i f i cb i n d i n go f
the anti-CD4 antibody. The stable TRN-SR2 knockdown
and control cell lines were challenged with wild type
HIV-1 NL4-3 and N74D CA mutant virus in a multiple-
round infection (Figure 4D), with the inocula normal-
ized for p24 content. Both viruses replicated with similar
kinetics in the shSCR control cells. The replication of
both the HIV-1 wild type virus and the HIV-1 N74D
CA mutant was severely impaired up to 10 days post
infection in both shTR3 and shTR4 HeLaP4 cell lines
stably depleted of TRN-SR2, although the N74D CA
mutant was somewhat less sensitive to TRN-SR2 knock-
down (10-fold inhibition in the shTR3 HeLaP4 cells
compared to shSCR cells) than the wild type virus (70-
fold inhibition in the shTR3 expressing cells compared
to shSCR cells). To exclude a non-specific effect of
TRN-SR2 knockdown or the expression of the different
shRNAs on the late steps of viral replication, we trans-
fected the shSCR, shTR3 and shTR4 HeLaP4 cell lines
with the viral molecular clone pNL4-3 and measured
the p24 levels in the supernatant 24 hours after transfec-
tion (Figure 4E). Although a slight inhibition of the p24
production was observed in the TRN-SR2 knockdown
cell lines, this difference could not account for the
potent inhibition of HIV replication in the TRN-SR2
depleted cells. These results confirm our previous find-
ing that TRN-SR2 depletion does not inhibit the late
steps of HIV replication [21] and exclude non-specific
effects on the late steps of HIV replication in the shTR3
and shTR4 expressing HeLaP4 cells compared to the
shSCR control cell line. Together, these results show
that the HIV-1 N74D CA mutant virus still requires
TRN-SR2 for efficient infection in HeLaP4 cells.
Next, we wondered whether the inhibition of the
N74D CA mutant by stable TRN-SR2 knockdown in the
multiple round infection experiments could be mirrored
in single round infection assays. We tested the infectiv-
ity of VSVG-pseudotyped wild type and N74D CA
mutant virus, or replication competent wild type and
N74D CA mutant viruses in single-round infection
experiments in the HeLaP4 cells stably depleted of
TRN-SR2 and in control cells. For these experiments,
we normalized the virus stocks for p24 content and for
RT activity (see the materials and methods section,
paragraph infection and transduction). Various amounts
of VSV-G pseudotyped HIV-1 NL4-3 and HIV-1 NL4-3
N74D CA mutant luciferase reporter viruses were used
Thys et al. Retrovirology 2011, 8:7
http://www.retrovirology.com/content/8/1/7
Page 6 of 17to infect the shSCR-, shTR3- and shTR4-expressing
HeLaP4 cells (Figures 5A and 5B). Infectivity was mea-
sured by Fluc activity. In these experiments, the pseudo-
typed N74D CA mutant virus again proved to be more
infectious than the wild type reporter virus (typically
10- to 15-fold). The results were comparable to the
experiments using HeLaP4 cells transiently depleted of
TRN-SR2 (Figure 3), excluding possible non-specific
effects on viral infectivity in the stable TRN-SR2 knock-
down cells due to off-target effects or selection.
The VSV-G pseudotyped HIV-1 N74D CA mutant
(Figure 5B), in contrast to the VSV-G pseudotyped wild
type virus (Figure 5A), did not require TRN-SR2 for
infection as was described in [32]. Single round infectiv-
ity of the VSV-G pseudotyped wild type virus was less
inhibited in the shTR4 TRN-SR2 knockdown cells (50%
inhibition on average) compared to the shTR3 expres-
sing TRN-SR2 knockdown cells (80% inhibition on aver-
age). This difference is likely due to the difference in the
extent of TRN-SR2 knockdown in these different cell
lines as measured by QPCR (compare Figures 5A and
4B). Next, we infected the HeLaP4 cells stably depleted
of TRN-SR2 and control cells with two different dilu-
tions of replication competent HIV-1 NL4-3 and N74D
CA mutant virus normalized for p24 values (and RT
activity) (Figures 5C and 5D). Single round infections
were performed in the presence of 5 μM of the protease
inhibitor ritonavir. b-galactosidase activity was measured
as readout for viral infectivity. The N74D CA mutant
was 2.5-fold more infectious than wild type HIV-1 in
these experiments, corresponding to the increase in
infectivity we observed in the experiments using transi-
ent siRNA-mediated knockdown of TRN-SR2 (Figures
3C and 3D). In the shTR3 HeLaP4 cells, we observed an
average reduction of 70% of wild type HIV-1 virus infec-
tion compared to shSCR cells, and in the shTR4 HeLaP4
cells an average reduction of 50% (Figure 5C), compar-
able to the experiments using VSV-G pseudotyped wild
TRN-SR2
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was inhibited 40% on average in the shTR3 cells, and 35%
on average in the shTR4 cells (Figure 5D). These results
point to a partial TRN-SR2 dependency of the N74D CA
mutant virus when carrying the HIV-1 envelope.
Different entry routes influence TRN-SR2 dependency of
the HIV-1 N74D CA mutant virus
The major endocytic pathways include pH-dependent
clathrin-mediated endocytosis, pH-independent caveo-
lae-mediated endocytosis, clathrin- and caveolae-inde-
pendent endocytosis, macropinocytosis and phagocytosis
(for a review see [43]). To investigate whether endocyto-
sis in general renders the HIV-1 N74D CA mutant insen-
sitive to TRN-SR2 knockdown, we produced wild type
and N74D CA mutant NL4-3 luciferase reporter virus
pseudotyped with the HIV-1 envelope glycoproteins,
VSV-G, or viral envelopes derived from the measles
virus, amphotropic MLV or Ebola virus. Both the HIV-1
envelope and the measles virus envelope mediate viral
entry via pH-independent fusion of the viral and cellular
membranes [44], although HIV-1 virions are also pro-
posed to enter cells via pH-independent endocytosis
leading to unproductive infection [45-47], or via endocy-
tosis and subsequent dynamin-dependent fusion with
endosomes [48]. The modes of entry of amphotropic
M L V( M L V a m p h o )a n dt h eh i g h l yp a t h o g e n i cE b o l a
virus have been the subject of debate, but recent studies
showed that MLVampho enters the cell via a pH-inde-
pendent, caveola-dependent endocytic pathway [49]
while the Ebola virus enters through pH-dependent cla-
thrin-mediated endocytosis [50]. VSV-G pseudotyped
viral particles enter target cells via pH-dependent endo-
cytosis, although the role of clathrin in this process is not
well understood [50-52]. Although we observed pre-
viously (Figure 4D) that the TRN-SR2 dependent pheno-
type of HIV-1 is more pronounced in prolonged multiple
round infections, pseudotyping of the wild type and
N74D CA mutant reporter viruses with different viral
envelopes obliged single round infection experiments.
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control cells were challenged with the differently pseu-
dotyped WT and N74D CA mutant reporter viruses and
infectivity was measured using the Fluc reporter protein
activity as readout. The infectivities of the pseudotyped
viruses were in a similar range in control cells when
envelopes mediating the same entry route were used
(Figure 6). When the HIV-1 N74D CA mutant reporter
virus was pseudotyped with VSV-G (Figure 6D) or the
Ebola envelope (Figure 6E), infections were not impaired
by TRN-SR2 knockdown in contrast to wild type repor-
ter virus. However, when the viral particles were pseu-
dotyped with the HIV-1 envelope (Figure 6A), the
MLVampho envelope (Figure 6B) or the measles virus
envelope (Figure 6C), the N74D CA mutant was still
dependent on TRN-SR2 (50% inhibition of infection in
TRN-SR2 depleted cells), although not as dependent as
the wild type virus (80-90% inhibition of infection).
These findings show that the HIV-1 N74D CA mutant
virus relies much less on TRN-SR2 when entering the
target cells via pH-dependent endocytosis (VSV-G and
Ebola envelope). After membrane fusion (HIV-1 and
measles virus envelope) or pH-independent endocytosis
(MLVampho envelope), the N74D CA mutant still
requires TRN-SR2 for infection of HeLaP4 cells.
Discussion
Lentiviral specificity of TRN-SR2
We initially identified TRN-SR2 in a yeast two-hybrid
screen searching for cellular binding partners of HIV-1
IN, and in the reverse screen no interaction with capsid
was detected. Subsequently we showed that TRN-SR2
mediates nuclear import of the HIV-1 PIC [21]. Since
o n eo ft h ek e yf e a t u r e so fl e n t i v i r u s e si st h e i ra b i l i t yt o
infect non-dividing cells, we questioned whether TRN-
SR2 is a lentiviral-specific cofactor of HIV-1 replication.
We challenged HeLaP4 cells depleted of TRN-SR2 with
VSV-G pseudotyped retroviral vectors derived from
HIV-1, SIV, EIAV, FIV or MLV, and the results
obtained were comparable with recently reported data
[30]. We also observed a TRN-SR2 independent pheno-
type for the FIV vector, and the MLV vector was only
slightly sensitive to TRN-SR2 depletion (Figure 1).
TRN-SR2 independent transduction by FIV, MLV and
RSV derived vectors has been shown before [21-23,30].
Lee et al. reported that a pseudotyped FIV vector was
insensitive to TRN-SR2 knockdown as well [32].
Together these data suggest that TRN-SR2 acts as a len-
tivirus-specific cofactor, although not all lentiviruses uti-
lize it to the same extent. Because of our finding that
VSV-G pseudotyping masks the TRN-SR2 requirement
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dent to extend this study in a follow up project by using
native viral envelopes or at least viral envelopes mimick-
ing the natural entry pathway of each specific virus
under study. HIV-1 and SIV are related lentiviruses and
both enter target cells predominantly via membrane
fusion. VSV-G pseudotyping did not alter the require-
ment of wild type HIV-1 for TRN-SR2 [21], although a
single mutation in the CA protein (N74D) abolished the
TRN-SR2 dependency of VSV-G pseudotyped HIV-1.
Although VSV-G pseudotyped SIV was highly sensitive
to TRN-SR2 knockdown, it would be interesting to test
SIV with its viral envelope which mediates fusion-based
entry. The EIAV virus is believed to enter the cell
through pH-dependent, clathrin-mediated endocytosis
[53], implying that VSV-G pseudotyping may actually
resemble the natural entry pathway for this virus; the
sensitivity for TRN-SR2 depletion of the pseudotyped
EIAV vector may well reflect its natural dependency on
TRN-SR2. The fusion-based mechanism of entry used
by the FIV virus closely resembles that of HIV and SIV
[54]. Both ecotropic and amphotropic MLV enter the
cell through a pH-independent endocytic pathway
[49,55]. When pseudotyping MLV and FIV one should
take the specific entry pathways into account. At this
stage, we cannot entirely exclude that FIV and MLV
require TRN-SR2 for their replication since all experi-
ments were performed with VSV-G pseudotyped vectors
(our data and [30,32]). Krishnan and colleagues tried to
correlate the binding affinities of recombinant TRN-SR2
for different retroviral integrases with the dependency
on TRN-SR2 displayed by the corresponding viral vec-
tors [30]. In the absence of any correlation, the authors
concluded that IN must not play a dominant role in the
TRN-SR2 requirement of HIV-1. However, our findings
p u ti n t oq u e s t i o nt h eT R N - S R 2 - r e l a t e dp h e n o t y p e s
observed for the different viral vectors since all experi-
ments described so far were performed using VSV-G
pseudotyped viral particles and not the natural virus
envelopes. Therefore, the conclusion that the require-
ment for TRN-SR2 during infection does not map to
HIV-1 IN [30] may be premature, and requires further
study on the retroviral specificity of TRN-SR2-mediated
nuclear import using replicating viruses instead of vec-
tors and the use of the respective host cells. Alterna-
tively, one could pseudotype viral vectors while
mimicking the natural entry mechanism to determine
the role of TRN-SR2 in the replication of each particular
virus. Although we don’t provide direct evidence for an
interaction between TRN-SR2 and HIV-1 IN in the con-
text of a viral PIC during infection, we believe our
results do not refute the hypothesis that IN plays a
direct role in the TRN-SR2-mediated nuclear import of
HIV.
Since the DNA flap has been implicated in nuclear
import [35-40], we compared the infectivity of both
HIV-1-derived VSV-G pseudotyped vectors and infec-
tious viruses with or without a functional DNA flap in
HeLaP4 cells depleted of TRN-SR2 (Additional file 1).
The flap-negative vectors and viruses were as sensitive
f o rT R N - S R 2d e p l e t i o na st h ev e c t o r sa n dv i r u s e sh a r -
boring a functional DNA flap, ruling out an important
role for the DNA flap in the TRN-SR2 requirement of
HIV-1 replication.
The MLV capsid renders pseudotyped HIV-1 largely
independent of TRN-SR2
To understand the TRN-SR2 independent phenotype of
the pseudotyped MLV vector observed in our previous
experiments, we used pseudotyped MHIV chimeric
viruses [6,31] to analyze the role of different viral factors
in the TRN-SR2 dependency of HIV-1 (Figure 2). Both
the pseudotyped MLV vector and the MHIV-
mMA12CA chimera carrying the MLV CA and MA
proteins in place of the corresponding HIV proteins
were much less dependent on TRN-SR2 than the HIV-1
parental vector. Contrarily, the pseudotyped MHIV-mIN
chimeric virus still required TRN-SR2 for infection of
HeLaP4 cells. Similar results were recently reported [30].
There are two possible explanations for our observa-
tions: TRN-SR2 may bind to the HIV-1 CA and/or MA
proteins but not to MLV CA and/or MA, or TRN-SR2
may bind to both HIV-1 IN and MLV IN. To investigate
the latter hypothesis, we measured the direct protein-
protein interaction between GST-TRN-SR2 and His-
tagged HIV-1 IN or MLV IN. Both integrases strongly
interact with TRN-SR2 and display similar dissociation
constants (HIV-1 IN Kd: 36.3 nM, MLV IN Kd:1 7 . 5
nM). While no physical interaction of TRN-SR2 and CA
has yet been demonstrated, our data are consistent with
TRN-SR2 interacting with the integrase protein during
viral replication in the cell. We have also previously
ruled out binding by TRN-SR2 to any other viral protein
apart from HIV-1 IN by reverse yeast two-hybrid
screening [21]. Although this result can explain the
TRN-SR2 dependency of MHIV-mIN, it does not
explain the TRN-SR2 independent phenotype of the
MHIV-mMA12CA virus and the MLV vector. It is well
known that the uncoating steps of HIV and MLV are
quite different [56]. During the early steps of retroviral
infection most of the CA proteins dissociate from the
HIV nucleoprotein complexes of incoming virions,
whereas a large amount of CA remains bound to the
MLV nucleoprotein complexes [57,58]. The uncoating
process may be the rate-limiting step determining
further downstream events such as the interaction with
TRN-SR2 and through that, the nuclear entry of the
PIC. According to this hypothesis, the MLV capsid may
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SR2. Alternatively, the presence of this capsid may alter
docking of the PIC to the appropriate nucleoporin
required for TRN-SR2 interaction, and, in so doing, the
capsid may determine the vehicle selected to cross the
nucleopore tunnel. Pseudotyping with VSV-G is
required in studies with chimeric MHIV viruses to over-
come their poor infectivity and to reach measurable
titers [6,31]. As we have dete r m i n e dt h a tp s e u d o t y p i n g
of viruses may mask the role of TRN-SR2 during viral
infection, we cannot exclude the possibility that MHIV-
mMA12CA still requires TRN-SR2 for infection after
viral entry mediated by fusion instead of endocytosis.
Therefore, we cannot conclude, based on our experi-
ments using the chimeric MHIV viruses and AlphaSc-
reen protein-protein interaction assays, that the
requirement for TRN-SR2 during infection does not
map to HIV-1 IN, as was proposed by Krishnan et al.,
based on their comparable results [30].
The viral entry route influences TRN-SR2 dependency of
the HIV-1 N74D CA mutant
In an elegant study, Lee and colleagues describe how an
HIV-1 CA mutant, N74D, renders HIV-1 resistant to a
block in replication imposed by the ectopic expression
of a C-terminally truncated version of CPSF6 [32]. Sur-
prisingly, VSV-G pseudotyped HIV-1 N74D CA mutant
virus was shown to efficiently infect both dividing and
non-dividing cells depleted of TRN-SR2. In the same
study, the nucleoporins (Nups) selected by pseudotyped
HIV-1 were shown to also depend on the single residue
change in CA. While pseudotyped wild type HIV-1 virus
was inhibited by knockdown of Nup153 and Nup160,
the pseudotyped HIV-1 N74D CA mutant virus was
impaired to a greater extent by knockdown of Nup85,
Nup155 and Nup160.
We have now demonstrated that the TRN-SR2
requirement for replication of the HIV-1 N74D CA
mutant strictly depends on the viral envelope chosen
(Figures 3, 4, 5 and 6). In a multiple round infection
experiment using HeLaP4 cells stably depleted of TRN-
SR2, which more closely resembles a natural occurring
HIV infection than single round infection assays, the
N74D CA mutant virus proved to be still dependent on
TRN-SR2 (Figure 4D), although to a somewhat lesser
extent than wild type HIV-1. When we pseudotyped
viral particles with the VSV-G (Figures 3A, B, 5A, B and
6D) or the Ebola virus envelope (Figure 6E), which both
mediate entry through pH-dependent endocytosis, the
mutant virus proved completely independent of TRN-
SR2. However, after pseudotyping the N74D CA mutant
with envelopes derived from MLVampho (Figure 6B) or
measles virus (Figure 6C) or in the presence of the wild
type HIV-1 envelope (Figures 3C, D, 5C, D and 6A), the
N74D CA mutant was intermediately impaired by TRN-
SR2 knockdown. HIV-1 and measles virus enter cells by
membrane fusion, while MLVampho uses a pH-indepen-
dent, caveola-dependent endocytic route. Both the multi-
ple round infections using p24 as readout (Figure 4D)
and the infection experiments using bioluminescent
reporter proteins to measure infectivity (Figures 3 and 5)
suggest that the TRN-SR2 independent phenotype dis-
played by the VSV-G pseudotyped HIV-1 N74D CA
mutant depends on the viral envelope mediating entry
into the target cell and the trafficking route, rather than
on a reduced interaction between CA and TRN-SR2 as
was hypothesized by Krishnan et al.[ 3 0 ] .I n t r i g u i n g l y ,
the partial dependence on TRN-SR2 suggests that the
N74D CA mutant is able to use an alternative nuclear
import pathway besides TRN-SR2-mediated nuclear traf-
ficking, especially when entering the cell via pH-depen-
dent endocytosis.
The reason why certain CA mutations abolish the
requirement for TRN-SR2 of HIV-1, especially when
pseudotyped, is currently unclear. It is known that the
HIV-1 CA protein interacts with different cellular cofac-
tors like cyclophilin A and restriction factors like
TRIM5a [59]. It is plausible that the N74D CA muta-
tion could inhibit or stimulate certain interactions of the
incoming viral cores with cellular cofactors or restriction
factors, thereby altering the structure of the PIC and
shielding the interaction with TRN-SR2. This may also
explain the higher infectivity of the HIV-1 N74D CA
mutant virus compared to wild type virus (Figures 3, 4,
5 and 6). Overall, the N74D CA mutant is more infec-
tious than the wild type virus in our hands, especially
when pseudotyped with the VSV-G envelope, and this
higher infectivity seems more pronounced in single
round infection assays using bioluminescence to mea-
sure infectivity.
It is also known that endocytosis-based uptake of vir-
ions in target cells, mediated by the VSV-G envelope,
changes the trafficking route followed by the incoming
viral particles during early steps of infection. After
entering the cell, viruses need to penetrate cortical
actin, the dense layer of actin microfilaments under-
neath the plasma membrane [60]. Endocytosis naturally
by-passes the cortical actin barrier and transports the
maturing viral cores deeper into the cytoplasm before
they are released from the endocytic endosomes [60,61].
It is possible that this different way of entry guides the
incoming viral cores to other trafficking routes along
the microtubuli. These re-routed PICs may dock even-
tually to different nucleoporins and interact with other
importins regulating nuclear import. Anderson and
Hope also suggest that the HIV-1 CA may direct viral
nucleoprotein complexes to a cytoplasmic pathway lead-
ing to efficient NPC trafficking before being shed from
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Hypothetically, the N74D mutant CA could direct PICs
to an alternative transport pathway and a different com-
partment of the nuclear membrane where an unknown
alternative import pathway is used. This may also
explain the reduced TRN-SR2 dependency of the N74D
CA mutant when carrying the HIV-1 envelope.
The velocity of particle trafficking and the speed of
uncoating might also affect the status of the PIC when
it reaches the nuclear membrane. Accelerated VSV-G
induced trafficking through the cytoplasm, combined
with a slower kinetics of uncoating due to CA muta-
tions, may result in the shielding of TRN-SR2 nuclear
localization signals when reaching the nuclear pore, for-
cing alternative import pathways to be selected. This
could explain why the N74D mutant loses its depen-
dency on TRN-SR2 in particular when combined with a
VSV-G envelope.
Finally, CA may be directly involved in docking of
PICs to the nuclear pore. Altered requirements of VSV-
G pseudotyped HIV-1 Q63A/Q67A, E45A and N74D
CA mutants for certain Nups, compared to wild type
virus, were indeed demonstrated [32]. If the N74D
mutation alters the selection of the specific Nup, alter-
native importins may be chosen for nuclear import,
which could also explain the reduced TRN-SR2 depen-
dency of the N74D CA mutant when carrying the HIV-1
envelope. The nature of these import factors still has to
be revealed.
Conclusion
Our data demonstrate that HIV-1 CA modulates nuclear
entry of VSV-G pseudotyped viruses. The role of CA in
nuclear import of viruses which retain their natural
envelopes also warrants further study, since the N74D
CA mutant is less dependent on TRN-SR2 for infection.
Our results argue for careful interpretation of experi-
ments performed with VSV-G pseudotyped viral parti-
cles when studying early steps in viral replication and
the role of CA in uncoating, trafficking, docking at the
NPCs and/or nuclear import. By playing a role in
uncoating, trafficking and/or docking, steps that all pre-
cede the site-specific interaction between IN and TRN-
SR2, CA may exert an indirect effect on the process of
nuclear import. PIC nuclear import remains a bottle-
neck process in the viral life cycle and the interaction
between HIV-1 IN and TRN-SR2 may provide an excit-
ing new drug target [62]. In order to design drugs that
can specifically interfere with the nuclear import of the
PIC, a better understanding of the exact mechanisms of
TRN-SR2-mediated nuclear import and possible other
import pathways is required. The data presented here
will aid in reaching this objective.
Materials and methods
Cell culture and siRNA transfections
HeLaP4 cells and 293T cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
50 μg/ml gentamicin (Gibco, BRL) and 10% fetal calf
serum (International Medical, Belgium). Cells were incu-
b a t e da t3 7 ° Ca n d5 %C O 2 in a humidified atmosphere.
Two different HeLaP4 cell lines stably knocked down
for TRN-SR2 were generated by transduction with two
different lentiviral vectors expressing shRNAs targeting
the TRN-SR2 mRNA, called shTR3 and shTR4 (Sigma,
clone-id NM_012470.2-867s21c1 and NM_012470.2-
2084s21c1). A control cell line was established using a
control vector expressing a scrambled shRNA referred
to as shSCR (Sigma, product number SHC002). These
lentiviral transfer plasmids were a kind gift from Dr. R.
Hoeben (Leiden University Medical Center, The Nether-
lands). The shRNA expressing transfer plasmids are
based on the pLKO.1 plasmid (Sigma) containing a pur-
omycin resistance cassette. After transduction cells were
selected and grown in DMEM as described above with
the addition of 1 μg/ml puromycin.
For siRNA transfections, 6 × 10
5 HeLaP4 cells were
plated per well in 6-well plates the day before transfec-
tion. The next day, 60 pmol of siRNA were transfected
using 15 μl siLentFect (Bio-Rad, Belgium) in a total
volume of 1 ml DMEM (10% serum, no antibiotics) per
well according to the manufacturer’s instructions. The
siRNA siTRN-SR_2 targeting the TRN-SR2 mRNA (5’
UCGGCGCACAGAAAUUAUAdTdT 3’)( Q i a g e n ,T h e
Netherlands) was previously characterized [21]. As a con-
trol for non-specific effects, we used siTRN-SR_2MM
targeting the same sequence but harboring 4 mutations
(bold) (5’ UCGGCGCAGUCUAAUUAUAdTdT 3’)a s
described [21]. Mock transfected cells were always ana-
lyzed in parallel.
Viruses and viral vectors
The viral molecular clones pNL4-3 and pNL4-3.Luc.R-
E- were obtained through the NIH AIDS Research and
Reagent Reference program, division of AIDS, NIAID,
NIH, and were used to produce wild type HIV-1 virus
and HIV-1 single-round luciferase reporter virus, respec-
tively. The construct pNL4-3.Luc.R-E- N74D CA encod-
ing a N74D CA mutant reporter virus was a kind gift of
Dr. V. KewalRamani (National Cancer Institute, Mary-
land). Plasmid pNL4-3 N74D CA was created by digest-
ing pNL4-3.Luc.R-E- N74D CA with BssHII and SpeI
and cloning this fragment into pNL4-3 digested with
BssHII and SpeI. Plasmids pNL4.3LAI cPPT and
pNL4.3LAI cPPTD were used to produce wild type con-
trol viruses or viruses harboring an inactive DNA flap
respectively as previously studied [38]. The following
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generous gifts from Dr. M. Emerman (Fred Hutchinson
Cancer Research Center, Washington) [6,31]. Plasmid
pLNCLuc is a MLV-derived retroviral transfer
plasmid for production of MLV-based vector particles.
Plasmid pLai3ΔenvLuc2 is an Env-deleted HIV-1 pro-
virus and was the parental construct for the following
HIV-based chimeric viruses (MHIV). The chimeric
clone pMHIV-mMA12CA harbors the MLV MA, p12
and CA coding sequences instead of the HIV-1 MA and
CA coding sequences [6]. In the chimeric clone
pMHIV-mIN the HIV-1 IN coding sequence is replaced
by the MLV IN coding sequence [31].
Viral vector production was performed as described
earlier [63,64]. Briefly, VSV-G pseudotyped viral vectors
were produced by triple polyethylenimine (PEI)-mediated
transfection of 293T cells using per 10 cm dish 5 μgo f
the envelope expression plasmid pMD.G [65] for expres-
sion of VSV-G, 10 μg of a packaging plasmid and 20 μg
of a transfer plasmid carrying a reporter gene flanked by
2 long terminal repeats. Two and three days after trans-
fection, the supernatant was harvested, filtered with 0.45
μm pore-size syringe filters (Sartorius) and concentrated
by centrifugal filtration using vivaspin concentrators (Sar-
torius). To produce viral vectors derived from HIV-1 we
used pCHMWS_eGFP-T2A-Fluc [64] and pCMVΔR8.91
[66] as transfer and packaging plasmid respectively; for
simian immunodeficiency virus (SIV) vectors we used
pGAE-CAG-eGFP-Wpre [67] and pAd-SIV3+ [68] (a
kind gift from Didier Nègre, Ecole Normale Supérieure,
Lyon); for feline immunodeficiency virus (FIV) pSM32
and pSP26 [69] (a kind gift from Yea-Lih Lin, Institut de
Génétique Humaine, Montpellier) were used; equine
infectious anemia virus (EIAV) vectors were produced
with p6.1G3CeGFPw (unpublished) and pEV53B [70]
(kind gifts from M. Patel and J.C. Olsen, University of
North Carolina, Chapel Hill) and for MLV-derived vec-
tors we used pLNC_eGFP-T2A-Fluc and pCMVgagpol
(Cell Biolabs, San Diego, CA). pLNC_eGFP-T2A-Fluc
was constructed by cloning the eGFP-T2A-Fluc expres-
sion cassette from pCHMWS_eGFP-T2A-Fluc into the
multiple cloning site in pLNCX (Clontech, Saint-Ger-
main-en-Laye, France). Transfer plasmids pCSGFPW and
pCASGFPW were used to produce lentiviral vectors har-
boring a DNA flap in sense or antisense orientation,
respectively [37].
For production of Env-deleted pseudotyped single-
round reporter viruses 20 μg of a viral molecular clone
plasmid and 5 μgo fa ne n v e l o p ee x p r e s s i o np l a s m i d
were cotransfected per 10 cm Petri dish. Plasmids pMD.
G [65] and pDOLHIVEnv [71] were used for pseudotyp-
ing viral particles with VSV-G or the HIV-1 envelope,
respectively. Plasmid pAmpho [72] was a kind gift from
Dr. M. Sena-Esteves (Massachusetts General Hospital,
Boston) and was used for pseudotyping viral particles
with the amphotropic MLV envelope. Plasmid
pEboZΔ6GP (NTDL6) [73] was a kind gift from Dr. J.
Wilson (Penn University, Philadelphia) and was used to
pseudotype viruses with the Ebola Zaire (EboZ) envel-
ope glycoprotein. Plasmids pCG-HcΔ18 and pCG-FcΔ30
[74] were a kind gift from Dr. C. Buchholz (Paul-Ehr-
l i c h - I n s t i t u t ,L a n g e n ) ,a n dw e r ec o t r a n s f e c t e d( 0 . 5μg
and 3.5 μg per Petri dish, respectively) during virus pro-
ductions for pseudotyping with the measles virus envel-
ope hemagglutinin and fusion protein, respectively. For
productions of single-round viral particles pseudotyped
by other envelopes than VSV-G, and for productions of
the MHIV chimeric viruses, concentrated virus preps
were used freshly and undiluted for infection because of
the poor infectivity of these viral preparations. For pro-
duction of wild type HIV-1 NL4-3 and NL4-3 N74D
CA, the cells were transfected with 20 μg plasmid
encoding the viral molecular clone. These viruses carry
the wild type HIV-1 envelope; they were not concen-
trated but stored at -80°C after harvest and filtration
through 0.45 μm pore-size syringe filters (Sartorius).
Infection and transduction
1×1 0
4 HeLaP4 cells transiently or stably depleted of
TRN-SR2 and control cells were seeded into 96-well
plates. Two days later cells were infected in triplicate
with 3 dilutions (typically 5 × 10
4,1×1 0
4 and 2 × 10
3
pg p24 unless described otherwise) of HIV-1 virus or
VSV-G pseudotyped single-round HIV-1 virus in a total
volume of 100 μl per well. p24 measurements were
done with the HIV-1 p24 ELISA kit of PerkinElmer, or
the INNOTEST HIV Antigen mAb kit of Innogenetics
for the experiments presented in Figure 5. Virus stocks
used in Figure 5 were also normalized for RT activity
using the commercially available HS-Lenti RT Activity
kit (Cavidi). We measured equal ratios of wild type and
N74D mutant virus in both the pseudotyped and repli-
cation competent virus stocks using both the Innoge-
netics p24 ELISA and the RT activity kit. The inocula
were replaced by fresh medium 24 h after infection.
Each well was lysed 72 h after infection using 50 μlo f
lysis buffer (50 mM Tris/HCl, pH 7.3, 200 mM NaCl,
0.2% NP40, 5% glycerol) and was analyzed for b-galacto-
sidase activity (chemiluminescent b-Gal Reporter Gene
Assay, Roche Applied Science, Belgium) or firefly luci-
ferase activity (ONE-Glo™, Promega, Belgium) accord-
ing to the manufacturer’s protocols. Chemiluminescence
was measured with a Glomax luminometer (Promega,
Belgium). The protein concentration of each sample was
determined (BCA Protein Assay Kit, Thermo Scientific
Pierce) and readouts were normalized to 1 μg total pro-
tein. The MHIV chimeric viruses and single-round viral
particles pseudotyped with other envelopes than VSV-G
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concentration.
When retroviral vectors expressing GFP were used for
transductions the inocula were adjusted to yield 30-60%
GFP positive control cells. Transduction was performed
3 days post transfection of siRNAs and vectors were
replaced by medium 24 h later. Three days post trans-
duction, cells were trypsinized and fixed in 2% parafor-
maldehyde prior to analysis with a FACSCalibur flow
cytometer (Becton-Dickinson, Franklin Lakes, NJ).
R e s u l t sa r ee x p r e s s e da so v e rall GFP fluorescence, i.e.%
transduced cells × mean fluoresence intensity. For mul-
tiple-round infections of the stable TRN-SR2 knock-
down HeLaP4 cells and control cells, 2 × 10
4 cells per
well were plated the day before infection in a 6-well
plate. The next day cells were infected with HIV-1 in a
total volume of 1 ml corresponding to 6 × 10
4 pg p24
as determined by p24 measurements (HIV-1 p24 ELISA
kit, PerkinElmer) of the viral stocks. Inocula were
replaced by 4 ml of fresh medium containing only 5%
fetal calf serum 24 h after infection. Four days after
infection sampling of the supernatants for p24 analysis
was started on a daily basis until cells reached complete
confluency.
For the analysis of the late steps of viral replication, 5 ×
10
5 HeLaP4 cells stably depleted of TRN-SR2 and control
cells were seeded in a 6-well plate and grown until 50%
confluency. Next 1 μg of pNL4-3 was transfected using
5 μl Fugene-6 according to the manufacturer’sp r o t o c o l .
6 hours after transfection cells were replenished with
1 ml fresh growth medium, and 24 hours after transfection
supernatants were collected to measure p24 production
(HIV-1 p24 ELISA kit, PerkinElmer). As a negative con-
trol, 5 μM of the protease inhibitor ritonavir was added to
the shSCR expressing control cells.
Recombinant protein purification
TRN-SR2 cDNA was amplified from pGEX-6P-1-TRN-
SR2 (kind gift from Dr. W.-Y. Tarn, Institute of Biomedi-
cal Sciences, Taiwan) using a forward primer (5’
AAAAGGATCCATGGAAGGAGCAAAGC 3’)c o n t a i n -
ing a BamHI site and a reverse primer (5’ AAAACTC-
GAGCTACTATCGAAACAACCTGG 3’) containing a
XhoI site. The PCR fragment was digested with BamHI
and XhoI and inserted into the pGEX-6P-2 plasmid
digested with BamHI and XhoI. GST-TRN-SR2 was puri-
fied using Glutathione Sepharose Resin (GE Healthcare,
Belgium) as described previously [21] with minor modifi-
cations. Plasmids pKBIN6H [75] and pETINH1 [76] were
used for expression of recombinant C-terminally His6-
tagged integrases derived from HIV-1 and MLV respec-
tively. C-terminally His6-tagged integrases were purified
by affinity and ion exchange chromatography as
described [75]. The expression construct for His6-tagged
human heterotrimeric G protein a oA subunit (His6-
GaoA) was kindly provided by Dr. D. Siderovski (Univer-
sity of North Carolina) and purified as described in [41].
His6-Roc-COR was purified via affinity and ion exchange
chromatography as described in [42].
AlphaScreen binding assay
The AlphaScreen binding assay (PerkinElmer) was per-
formed in a total volume of 25 μl per well in 384-well
Optiwell™ microtiter plates (PerkinElmer). Appropriate
dilutions of recombinant GST-TRN-SR2 and IN-His6
were added to 5 μl of the assay buffer (25 mM Tris/HCl,
pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.1% (v/v) Tween-
20, 0.1% (w/v) BSA) to a total volume of 15 μla n dt h e
microtiter plates were incubated for 1 h at 4°C. Next, 10
μl of a mix of glutathione donor and nickel-chelate
acceptor beads (PerkinElmer) (final concentration of 20
μg beads/ml) were added. Plates were then incubated for
1.5 h at room temperature and analyzed using an EnVi-
sion Multilabel Reader (PerkinElmer) according to the
manufacturer’s instructions. The assay was initially opti-
mized for the interaction between GST-TRN-SR2 and
HIV-1 IN-His6 by cross-titrations. A final concentration
of 10 nM GST-TRN-SR2 was determined as optimal to
avoid binding curve perturbation while still yielding a
high signal-to-noise ratio (> 35). Subsequently, concen-
trations ranging from 1 to 150 nM of recombinant His6-
tagged GaoA,R o c - C O R ,H I V - 1I No rM L VI Np r o t e i n s
were used to titrate GST-TRN-SR2. Each titration was
performed in duplicate and assays were independently
repeated. The equilibrium dissociation constants (Kd)
were calculated with GraphPad Prism 5.
Antibodies
For western blotting, protein concentrations of 1% SDS
whole cell extracts were determined using the BCA pro-
tein assay (Thermo Scientific Pierce) and after separa-
tion by SDS-PAGE 30 μg of each extract was
electroblotted onto polyvinylidene difluoride mem-
branes. Membranes were probed with monoclonal anti-
bodies against TRN-SR2 (1:100 dilution) (Genway
biotech, USA), b-tubulin (1:10000 dilution) (Sigma) anti-
bodies were used to confirm equal loading. Detection
was performed using horseradish peroxidase-conjugated
goat anti-mouse antibody (Dako) and chemilumines-
cence (ECL+, Amersham Biosciences). For FACS analy-
sis of CD4 expression levels, 4 × 10
5 HeLaP4 or 293T
cells were incubated with 5 μl R-phycoerythrin-conju-
gated anti-human CD4 antibody (Miltenyi Biotec) in a
total volume of 150 μl PBS for 0.5 hour at 4°C. After
incubation cells were washed with PBS, resuspended in
2% paraformaldehyde and analyzed by FACS.
Thys et al. Retrovirology 2011, 8:7
http://www.retrovirology.com/content/8/1/7
Page 14 of 17Quantitative PCR (QPCR)
To determine TRN-SR2 mRNA levels, RNA was
extracted from 2 × 10
6 HeLaP4 cells using the Aurum
total RNA Mini Kit (BioRad). 5 μg of total RNA was
reverse transcribed to cDNA in 100 μlt o t a lv o l u m e
using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). cDNA corresponding to 25 ng
of RNA was used to amplify TRN-SR2 mRNA or
b-actin mRNA using the iQ Supermix (BioRad) and
in-house designed primers and probes. Reactions and
analysis were performed with the iQ5 Multicolor RT
PCR Detection system and iQ5 Optical System software
(BioRad). Each reaction contained 12.5 μli QS u p e r m i x ,
5 μl cDNA, 100 nM or 200 nM forward primer, 100 nM
or 200 nM reverse primer, 100 nM or 200 nM probe
and water in a total volume of 25 μl for the detection of
b-actin or TRN-SR2 mRNA, respectively. Primers and
probe used for TRN-SR2 mRNA amplification and
detection were: forward primer, 5’-CTACCAGATGTG
GCTGAAGT-3’; reverse primer, 5’-ACAAAAAGTCG
GTCTGTCAA-3’;p r o b e ,5 ’-FAM-GCTCTGGGAGATC
ATGCAGG-TAMRA-3’.F o rb-actin mRNA detection
we used: forward primer, 5’-CACTGAGCGAGGCTA-
CAGCTT-3’; reverse primer, 5’-TTGATGTCGCGCAC-
GATTT-3’;p r o b e ,5 ’-HEX-ACCACCACGGCCGAGC
GG-TAMRA-3’. Each sample was run in triplicate for 3
minutes at 95°C followed by 50 cycles of 10 seconds at
95°C and 30 seconds at 55°C.
Additional material
Additional file 1: Supplementary Figure 1. The DNA flap does not
affect the TRN-SR2 dependency of HIV-1 replication. (A) HeLaP4 cells
depleted of TRN-SR2 (siTRN-SR_2) and control cells (mock and siTRN-
SR_2MM) were challenged using 3 dilutions of an HIV-1-derived VSV-G
pseudotyped viral vector harboring a functional wild type DNA flap (WT)
or (B) with a flap-negative (Flap-) vector. Both vectors express GFP. Three
days post transduction the overall GFP fluorescence in the cells was
analyzed by FACS. Graphs show the mean values of GFP fluorescence ±
SD of one representative experiment out of two performed in triplicate.
(C) Same experiment as in (A), but using multiple-round HIV-1 NL4-3
(WT) or (D) HIV-1 NL4-3 flap-negative (Flap-) infectious viruses. Three days
post infection b-gal activity was measured and normalized to the total
amount of protein in the cell lysates. Graphs show the mean values of b-
gal light units per μg protein (b-gal LU/μg protein) ± SD of one
representative experiment out of two performed in triplicate.
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